anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High-dose vitamin B12 is a potential treatment for patients with vasodilatory shock that is refractory to other therapies. Vasodilatory shock is characterized by low blood pressure and low systemic vascular resistance. Nitric oxide and hydrogen sulfide, two potential targets of high-dose vitamin B12 given as hydroxocobalamin, facilitate this syndrome. This review explores the relationship between high-dose vitamin B12 and hemodynamic outcomes in adults with vasodilatory shock and provides an update on the literature since a 2019 review on this topic. A literature search of studies published in the past 5 years was conducted in the CINAHL, PubMed, Cochrane, and EMBASE databases in May 2023. After assessing for eligibility, eight studies met this review's inclusion criteria. Seven of the eight studies reported decreased vasopressor requirements for part or all of the study samples after receiving a hydroxocobalamin infusion. However, not all patients responded to hydroxocobalamin. These findings are limited by patient selection and differences in the timing of vasopressor requirement and blood pressure outcome assessments. The current evidence is promising as to whether vitamin B12 , given as a hydroxocobalamin infusion, may improve hemodynamic outcomes in vasodilatory shock, but the evidence is of low quality. The use of hydroxocobalamin to treat refractory, vasodilatory shock remains investigative. Larger randomized controlled trials are required to elucidate the role of vitamin B12 in treating refractory, vasodilatory shock, including in conjunction with other alternative therapies such as methylene blue and corticosteroids.
PURPOSE:To obtain a cosmetic which is excellent in formability and impact resistance and also having excellent operability, transparency of the finished product and coloring properties while holding smoothness characteristic&to spherical powder and usability free from oily feeling. CONSTITUTION:This solid powder cosmetic contains 250wt.% of spherical powder based on the total amount of the cosmetic, a water-soluble polymer and an oil component. The water-soluble polymer can be selected from a mucopolysaccharide, a natural water-soluble polymer compound and a synthetic water-soluble polymer compound. Preferably, a salt of hyaluronic acid and carboxymethylcellulose sodium salt are preferable in view of formability. The compounding ratio of the water-soluble polymer is 0.1-10wt.%, preferably 0.5-5wt.%, based on the total amount of the cosmetic. The content of the oil component is as much as needed for the coloring of a color material and is not specified. However, the amount age as possible, e.g 3-5wt.%, is preferable in of view of the durability of color. As the spherical powder, powder of a resin, e.g. polyethylene, polystyrene, nylon, methyl polymethacrylate, silica, polymethylsilsesquioxane or silicone is used.
After approval by the ethics committee of the patients Faculty of Dentistry, University of São Paulo that having root canal filling of primary teeth will be invited to participate in the study. A clinical examination and prior radiographic diagnosis and also a quality of life questionnaire regarding oral health (- ECOHIS Early Childhood Oral Health Impact Scale) will be-held. The patient will be randomized to one of two groups and will be held endodontics by a blind handler. The patient will be accompanied with periods of one week, six months, 12 months and 24 months by a blinded evaluator. At the last visit of the review ECOHIS questionnaire will be reapplied to those responsible. The outcome will be the success or failure of endodontic treatments evaluated through permanent tooth in the arch on clinical and radiographic conditions of normality. The longevity of the treatments will be evaluated by estimating survival rates by Kaplan-Meier. The differences between the survival rates according to the type of proposed endodontic treatment will be analyzed using the log-rank test with a minimum significance level of 5%.
Many older adults live with some form of hearing loss and have difficulty understanding speech in the presence of background sound. Experiences resulting from such difficulties include increased listening effort and fatigue. Social interactions may become less appealing in the context of such experiences, and age-related hearing loss is associated with an increased risk of social isolation and associated negative psychosocial health outcomes. However, the precise relationship between age-related hearing loss and social isolation is not well described. Here, we review the literature and synthesize existing work from different domains to propose a framework with three conceptual anchor stages to describe the relation between hearing loss and social isolation: within-situation disengagement from listening, social withdrawal, and social isolation. We describe the distinct characteristics of each stage and suggest potential interventions to mitigate negative impacts of hearing loss on social lives and health. We close by outlining potential implications for researchers and clinicians.
SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and intense episodes of pain, which are called "sickle cell crises." The Comprehensive Sickle Cell Centers (CSCC) is a network of 10 centers that conduct research to improve health care and treatment options for people with SCD. This study, the Collaborative Data Project (C-Data), will establish a comprehensive database of children and adults receiving medical care at participating CSCC research centers who are potentially eligible for inclusion in SCD clinical trials. The main purposes of this study are the following: 1) to gather medical information about a large number of people with SCD over a long period of time; 2) to identify potential participants for future SCD clinical trials; 3) to collect information about how SCD affects quality of life; and 4) to evaluate the relationship between SCD patients' characteristics and medical events.

In this study, research staff will review participants' medical records twice a year for at least 5 years. Information will be collected regarding participants' medical history, physical exams, blood tests, and demographics. Once a year, participants will take part in a short interview about their health and lifestyle. Participants will also complete quality-of-life and patient satisfaction questionnaires during the first year of the study and may complete additional questionnaires in the future. During an interview, participants will be asked general questions about their experience with SCD and more specific questions on headaches and any possible relation they may have to SCD pain. Participants may also be asked to provide a blood sample at some point during the study. CSCC researchers will analyze the information in the database and may contact participants in the future to see if they are interested in enrolling in SCD clinical trials.
This study examines the influence of body mass index (BMI) on the relationship between quantitative sensory testing measures and clinical characteristics in fibromyalgia syndrome (FMS). Utilizing BMI as a categorical covariate (≥25 or ≥30 kg/m²) in associations between quantitative sensory testing metrics (pain-60, conditioned pain modulation, and temporal summation of pain [TSP]) and FMS clinical features, we explored BMI's role as both a confounder (change-in-estimate criterion-change equal or higher than 10%) and effect modifier (interaction term). Significant interactions revealed overweight/obese BMI as a modifier in the relationship between conditioned pain modification and both depression and symptom impact, with a homeostatic relationship between better clinical profile and pain inhibitory response observed solely in the normal-weight group. Similar results were found for pain-60 and depression. Additionally, BMI ≥30 kg/m² modified TSP's effect on pain, demonstrating lower pain with increased TSP, exclusively in the nonobese group. This study highlights the significant role of BMI in moderating the relationships of important pain inhibitory control processes and pain intensity, depression, and the overall impact of FMS symptoms. Our results suggest that high BMI states disrupt the homeostatic effects of pain inhibition, reducing its salutogenic response in FMS participants. We discuss the mechanistic and therapeutic implications of targeting BMI in FMS clinical trials and the potential impact of this important relationship. PERSPECTIVE: This investigation highlights the disruptive influence of high BMI on pain inhibitory control in fibromyalgia, unbalancing clinical symptoms such as pain and depression. It underscores the necessity of integrating BMI considerations into therapeutic approaches to enhance pain management and patient outcomes.
FIELD: tobacco industry.SUBSTANCE: present invention relates to a liquid formulation for the introduction of nicotine in the form of a free base or a salt thereof. Composition consists of: (I) from 12 to 28 wt. % of water; (II) at least 70 wt. % of propylene glycol; and (III) from 2 to 10 wt. % of said nicotine in form of a free base or salt thereof. Said liquid does not contain glycerine and ethanol. Present invention also relates to a method of administering nicotine in the form of a free base or a salt thereof into a human body by inhaling an aerosol of said liquid composition. Also described is an aerosol generation device and a reservoir for such a device containing said liquid composition.EFFECT: according to the invention, the liquid composition containing nicotine provides minimizing visibility of the created aerosol, better retention in the oral cavity and respiratory tract.10 cl, 7 tbl, 5 ex
Twenty-nine patients with Parathyroid Carcinoma were enrolled in a single-arm, open-label study. The study consisted of two phases, a dose-titration phase and a maintenance phase. Patients initially received 30 mg cinacalcet twice daily and then were titrated every 2 weeks to a maximum dose of 90 mg four times daily. Dosage escalation during the variable-length (2 to 16 weeks) titration phase continued until the serum calcium concentration was ≤ 10 mg/dL (2.5 mmol/L), the patient reached the highest possible dosage, or adverse events precluded further dosage increases.

Twenty-nine patients entered the study. The median exposure to cinacalcet was 229 days (range: 1 to 1051). At baseline the mean (SE) serum calcium was 14.1 (0.4) mg/dL. At the end of the titration phase, the mean (SE) serum calcium was 12.4 (0.5) mg/dL, which is a mean reduction of 1.7 (0.6) mg/dL from baseline. Figure 3 illustrates mean serum calcium (mg/dL) over time for all patients still on study at each time point from the beginning of titration to study visit week 80. Daily dose during the study ranged from 30 mg twice daily to 90 mg four times daily.

Figure 3. Serum Calcium Values in Patients with Parathyroid Carcinoma Receiving cinacalcet at Baseline, Titration, and Maintenance Phase

n = Number of patients with non-missing values at the timepoint.   
End of Titration (EOT) phase could occur at any visit from week 2 to 16. Patients at EOT are those who completed titration.
Transdermal therapeutic system for topical and systemic application of active agents includes at least one compound chosen from cpds. (A), from which nitrogen oxide is released by human or animal metabolism and cpds (B) which release NO in the organism. Nitrate esters and molsidomin are specifically excluded. Pref. compsn. contains arginine or a deriv., a cpd. with a gp. SNO, (a) or (b), a cpd. of formula (I), a sodium nitroprusside, or nitroso iron (II) sulphate, R1 and R2 = 1-12C alkyl without an branch, or benzyl, or NR1R2 = pyrrolidino, piperidino, piperazino or morpholine; an M<x+> = a cation; and x = the valency of the cation. USE/ADVANTAGE - The compsn. is used to treat NO- deficiency, high blood pressure, arterial spasms, platelet aggregation arteriosclerosis, to influence immunological and inflammatory process, to improve transfer of around signals in the central and peripheral nervous system, to relax the corpus cavernosum and to combat tumour cells. The compsn. releases the active agent steadily over a long time.
A homogeneous, stable cosmetic cream contains fine bubbles of air or inert gas dispersed uniformly in the mass, giving a soft, light foam with density below 0.8 g/cc and a light texture. The cream may contain, as extender, an aq. protein soln., as a foam contg. air or inert gas, esp. a soln. of albumen from beaten egg, or of vegetable or animal proteins rendered hydrophilic by hydrolysis. It contains the typical constituents of day and night creams for the face, creams for the and or body, softening or moisturising creams, cold cream, cream for removing make-up, and anti-sun creams. Components include fats, liq. or pasty hydrocarbons, detergents, surfactants, softeners, moisturisers, agents protecting against the cold and other external factors, stabilisers, preservatives against germs and micro-organisms, UV screens, and water, esp. lanolin and derivs., sterols, phospholipids, vaseline, mineral oils, paraffin, etc. ADVANTAGE - The cream may contain up to 10-15 wt.% of animal or vegetable protein without loss of stability. (7pp Dwg.No.0/0)
Extract (I) of orchid genus Vandaobtained from at least a part of an orchid species of Vanda denisoniana, is claimed. An independent claim is included for cosmetic or dermatological composition, comprising (I) dissolved or dispersed in an excipient, compatible with a topical application on the skin. ACTIVITY : Dermatological; Antiinflammatory. MECHANISM OF ACTION : Matrix metalloproteinase 2 (MMP2) inhibitor; MMP9 inhibitor; Cytokine production inhibitor; Interleukin IL-8 inhibitor; Prostaglandin E2 inhibitor. The ability of (I) to inhibit MMP2 was tested in human skin fibroblasts and kerationcytes cells. The result showed that extract of stem of Vanda denisonianaexhibited the percentage of inhibition of 97%.
Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
The invention relates to application of deferiprone in preparation of a novel coronavirus infection resistant drug. The invention screens out molecular deferiprone capable of inhibiting virus proliferation based on metabolic network simulation and chemical informatics methods. Through in vitro experimental study on the cell line level, the potential safety and effectiveness of the molecule in treating patients with novel coronavirus pneumonia are verified. In vitro cell experiments prove that the deferiprone has an IC (integrated circuit) on novel coronaviruses (original strains)  50  Minimum up to 2.077.+ -. 1.083uM (HPAEPIC cell line), toxicity to host cells CC  50  >200uM. Deferiprone has been shown to be useful as an inhibitor of novel coronaviruses for the prevention and treatment of novel coronavirus infections. The new deferiprone used as an old drug has no problem on safety, so that the deferiprone can be applied to clinic.
A method and an apparatus for introducing information into a living organism reliably and in a way which is unlikely to disturb the original function of the living organism. Information to be introduced into a biogenic DNA is prepared in a step. This information is compressed in the next Step. The compressed data is converted into base sequence data in the next step. The base sequence data has an error correction code inserted thereinto in the next step, has a buffer sequence inserted thereinto in the next Step, and has a sequence for positive selection inserted thereinto in the next step. If the position of introduction is determined in the next step to be a sequence complementary to the untranslated region, then an intron sequence is added. If the position of introduction is determined in the next step to be intron, then the next step is skipped and the position for introduction (which has the least effect on the living organism) is determined in the following step immediately after the skipped step. The present invention may be applied to genetically modified foods. <IMAGE>
PROBLEM TO BE SOLVED: To provide a new peptide obtained by the culture of Lactococcus lactis, Lactococcus confusus, etc., having a specific amino acid sequence, exhibiting angiotensin I converting enzyme inhibiting action and useful for the prevention and treatment of hypertension, etc. SOLUTION: This new peptide having angiotensin I converting enzyme inhibiting action is expressed by the formula I and the formula II. It inhibits angiotensin I converting enzyme having an action to convert angiotensin I into angiotensin II which is a strong hypertensive peptide and is effective e.g. for the prevention and treatment of hypertension. The peptide can be produced by dissolving skim milk in water, sterilizing at 115 deg.C for 20min, inoculating at least one kind of microorganism selected from Lactococcus lactis subsp. lactic (FERM P-13647) and Lactococcus confusus (FERM P-13646), fermenting at 30 deg.C for 24hr and collecting the produced peptide.
The invention discloses lactobacillus plantarum KSFY01 and application thereof, belonging to the field of microorganisms. The strain is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, the preservation number is CGMCC NO.15654, the preservation address is No. 3 of Xilu No.1 of Beijing province of south China, morning district, and the preservation date is 2018, 04 and 28 days. According to the invention, the antioxidation effect of the strain KSFY01 and the effect of improving the transportation capacity of the mouse are researched by establishing a mouse aging model. The experimental result shows that the strain can improve the anti-fatigue capability and the exercise capability of aged mice by improving the accumulation of metabolites, glycogen storage, muscle and liver-kidney damage and oxidative stress. Provides reference for developing food-borne antioxidants for resisting fatigue and improving the motion function of the old in the future, and has important significance for developing and utilizing probiotic resources.
Methods for increasing osteoinductivity and/or surface area of bone material are provided. The methods include providing bone material and dehydrating the bone material with a solvent at its critical point. A useful solvent for critical point dehydrating is carbon dioxide. Critical point dehydration resulting in increased osteoinductivity and/or surface area can be applied to many types of bone material including bone particles, bone chips, bone fibers, bone matrices, both demineralized and non-demineralized. An implantable composition having an enhanced osteoinductivity and/or osteoconductivity is also provided. The implantable composition contains demineralized bone matrix dried at critical point of carbon dioxide. Critical point dried fibers of a demineralized bone matrix have a BET value from about 40 m 2 /gm to about 100 m 2 /gm, a value that is 100 times higher than corresponding vacuum dried or lyophilized DBM fibers.
Ultrasound-guided erector spinae plane block (ESPB) is currently used as a component of multimodal analgesic regimen in a multitude of indications but the mechanism by which it produces anterior thoracic analgesia remains a subject of controversy. This is primarily the result of ESPB's failure to consistently produce cutaneous sensory blockade (to pinprick and cold sensation) over the anterior hemithorax. Nevertheless, ESPB appears to provide 'clinically meaningful analgesia' in various clinical settings. Lately, it has been proposed that the discrepancy between clinical analgesia and cutaneous sensory blockade could be the result of differential nerve blockade at the level of the dorsal root ganglion. In particular, it is claimed that at a low concentration of local anesthetic, the C nerve fibers would be preferentially blocked than the Aδ nerve fibers. However, the proposal that isolated C fiber mediated analgesia with preserved Aδ fiber mediated cold and pinprick sensation after an ESPB is unlikely, has never been demonstrated and, thus, without sufficient evidence, cannot be attributed to the presumed analgesic effects of an ESPB.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to concentrate used for preparing anti-allergic anti-inflammatory agent. Invention involves concentrate for preparing anti-allergic anti-inflammatory agent obtained from Staphylococcus aureus C2, strain GISK 222 after thermophilic stage of development and treatment with carbolic acid providing destruction of microorganisms and presenting product with protein content 0.5-1.0 mg/ml and lipid content 1.0-7.0 mg/ml. The advantage of invention involves preparing semi-finished product that can be used for end product preparing in any moment and stable at storage. EFFECT: improved method of preparing, valuable medicinal properties. 2 cl, 2 tbl, 2 ex
BACKGROUND: Stress is associated with negative health outcomes in adults, including increased adiposity. Eating behaviors to cope with stress can have a negative effect on adiposity. There is limited research on positive eating behaviors, such as intuitive eating (IE), and their relationship to stress and adiposity. Thus, this study aimed to examine the association between stress and adiposity and to assess whether IE is a mediator of that pathway.
METHODS: Data were analyzed from a cross-sectional study of 114 women between 40-64 years of age. Participants completed in-person visits and self-reported questionnaires, including the Intuitive Eating Scale and Perceived Stress Scale. Adiposity was assessed using dual energy x-ray absorptiometry. Measurements included total body fat percentage and android/gynoid (AG) ratio as a measure of abdominal adiposity. Participants provided ten salivary cortisol samples over two days, collected upon waking, 30-, 45-, and 60-minutes after waking, and prior to bed. Several methods were used to characterize cortisol secretion and exposure, including the diurnal cortisol slope and the cortisol area under the curve with respect to ground (AUCg). Linear regression was used to assess the associations between perceived stress and IE and between features of diurnal cortisol and IE. Mediation models were tested to examine the indirect effects of IE on the relationship between perceived stress and adiposity and to test the indirect effects of IE on the relationship between cortisol measures and adiposity.
RESULTS: Linear regression analyses indicated that higher cortisol AUCg was associated with lower scores on the eating for physical reasons subscale (β: -0.01, p = 0.008). After adjusting for covariates, neither higher perceived stress nor diurnal cortisol were associated with intuitive eating. There was no evidence of mediation of the association of stress on adiposity through IE.
CONCLUSION: Our findings demonstrate a relationship between higher overall morning cortisol and lower scores on the eating for physical reasons subscale of the Intuitive Eating Scale. Future research should seek to understand how intuitive eating may be used as a technique for individuals who engage in emotional eating to cope with stress, and to prevent excess adiposity resulting from stress in midlife women.